Daliresp (Forest Laboratories, Inc.)
Welcome to the PulseAid listing for the Daliresp drug offered from Forest Laboratories, Inc.. This Phosphodiesterase 4 Inhibitor [EPC],Phosphodiesterase 4 Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Forest Laboratories, Inc. |
NON-PROPRIETARY NAME: | roflumilast |
SUBSTANCE NAME: | ROFLUMILAST |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Phosphodiesterase 4 Inhibitor [EPC],Phosphodiesterase 4 Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2011-02-28 |
END MARKETING DATE: | 0000-00-00 |
Daliresp HUMAN PRESCRIPTION DRUG Details:
Item Description | Daliresp from Forest Laboratories, Inc. |
LABELER NAME: | Forest Laboratories, Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 500(ug/1) |
START MARKETING DATE: | 2011-02-28 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0456-0095_d2f4a26b-c233-4192-8eec-f08caf7965c6 |
PRODUCT NDC: | 0456-0095 |
APPLICATION NUMBER: | NDA022522 |
Other ROFLUMILAST Pharmaceutical Manufacturers / Labelers: